Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease
NCT01066442
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
273
Enrollment
OTHER
Sponsor class
Conditions
Parkinson's Disease
Interventions
DRUG:
BF2.649 (Pitolisant)
Sponsor
Bioprojet